Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II

Speciality: Oncology

Description:

A warm welcome to all the medical professionals joining this insightful session on the role of pazopanib in managing advanced renal cell carcinoma (RCC).

Kidney cancer, also known as renal cancer, is one of the more common cancers affecting both men and women, and its global burden continues to rise steadily. Advanced RCC, which corresponds to stage 4 kidney cancer, poses significant challenges in treatment and is often not curable.

Typically, healthcare providers focus on slowing disease progression, alleviating symptoms, and enhancing the quality of life for patients. However, continuous advancements in oncology research have led to the development and FDA approval of promising new treatment options.

Pazopanib is an anti-cancer agent that works by inhibiting tumor cell growth through multiple mechanisms. It targets key proteins, primarily tyrosine kinases, located on the surface of cancer cells. Many of these proteins play a critical role in angiogenesis, the process of forming new blood vessels that feed tumor growth.

We encourage you to stay engaged in this webinar, absorb the latest clinical insights shared by experts, and follow HiDoc for more such valuable sessions focused on advancing medical knowledge and practice.

See More Webinars @ Hidoc Webinars